Baker BROS. Advisors LP Takes Position in BioNTech SE (NASDAQ:BNTX)

Baker BROS. Advisors LP bought a new position in BioNTech SE (NASDAQ:BNTX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 45,031 shares of the company's stock, valued at approximately $5,131,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. SG Americas Securities LLC boosted its holdings in shares of BioNTech by 412.3% in the 4th quarter. SG Americas Securities LLC now owns 41,470 shares of the company's stock worth $4,726,000 after acquiring an additional 33,375 shares in the last quarter. Mirabaud & Cie SA acquired a new position in BioNTech in the fourth quarter worth $684,000. Bank of New York Mellon Corp grew its holdings in shares of BioNTech by 4.3% during the fourth quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company's stock worth $419,000 after purchasing an additional 150 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in shares of BioNTech in the fourth quarter valued at $1,118,000. Finally, Van ECK Associates Corp lifted its position in BioNTech by 25.1% during the 4th quarter. Van ECK Associates Corp now owns 118,418 shares of the company's stock worth $13,493,000 after buying an additional 23,733 shares in the last quarter. Institutional investors own 15.52% of the company's stock.

BioNTech Stock Down 6.3 %

BioNTech stock traded down $6.36 during mid-day trading on Tuesday, reaching $94.74. The company's stock had a trading volume of 1,841,711 shares, compared to its average volume of 916,342. The business's 50 day simple moving average is $99.87 and its 200 day simple moving average is $109.87. BioNTech SE has a 12 month low of $76.53 and a 12 month high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The company has a market capitalization of $22.73 billion, a price-to-earnings ratio of -45.11 and a beta of 1.35.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.38 by $0.70. The company had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business's revenue was down 19.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.90 EPS. As a group, research analysts anticipate that BioNTech SE will post -3.88 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on BNTX. Citigroup restated a "buy" rating and issued a $140.00 price objective (down previously from $145.00) on shares of BioNTech in a research report on Tuesday. Truist Financial began coverage on BioNTech in a report on Friday, January 10th. They set a "buy" rating and a $172.00 price objective for the company. Morgan Stanley reduced their price objective on shares of BioNTech from $140.00 to $132.00 and set an "overweight" rating on the stock in a research note on Tuesday. HC Wainwright dropped their target price on shares of BioNTech from $150.00 to $145.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Finally, Canaccord Genuity Group reiterated a "buy" rating and issued a $171.44 price objective on shares of BioNTech in a report on Tuesday, March 11th. Three analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $142.73.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.